ScholarX: CHOI, CHEL HUN

Detailed Information

CHOI, CHEL HUN (최철훈)

Medicine (Medicine)

Research Area

Tel 02-3410-3545
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Prognosis:24||Survival:17||Uterine cervical neoplasms:16||Cervical cancer:15||Recurrence:14||Laparoscopy:14||prognosis:12||cervical cancer:10||Chemotherapy:8||Ovarian neoplasms:7||Epithelial ovarian cancer:7||Ovarian Neoplasms:7||Minimally invasive surgery:7||Gynecology:6||Endometrial cancer:6||Hysterectomy:5||Laparoscopic surgery:5||recurrence:5||Borderline ovarian tumors:5||ovarian neoplasms:5||Adenocarcinoma:5||survival:5||Radiotherapy:5||Radical hysterectomy:4||immunohistochemistry:4||Pregnancy:4||Ovarian neoplasm:4||Epithelial Ovarian Cancer:4||epithelial ovarian cancer:4||Prognostic factor:4||laparoscopy:4||Conization:3||Cervical Cancer:3||Ovarian Cancer:3||Magnetic resonance imaging:3||Singleport:3||ovarian cancer:3||Bevacizumab:3||Surgery:3||Borderline ovarian tumor:3||Cisplatin:3||Paclitaxel:3||Clear cell carcinoma:3||cervical intraepithelial neoplasia:3||One port:3||Early cervical cancer:3||Lymph Node Excision:3||HPV:3||Ovarian cancer:3||hysterectomy:3||radical hysterectomy:2||DNA ploidy:2||chemotherapy:2||cisplatin:2||Mesothelial cell:2||Geriatric Assessment:2||Single port access:2||Single port access (SPA):2||siRNA:2||Singleport access:2||Colorectal cancer:2||sphingosine kinase 1:2||concurrent chemoradiation:2||squamous cell:2||Patientderived xenograft:2||Cervical neoplasms:2||MicroRNA:2||Stage:2||surgery:2||BRCA1:2||targeted therapy:2||Concurrent chemoradiotherapy:2||AZD4547:2||LESS:2||endometrial cancer:2||Carboplatin:2||Survival analyses:2||uterine cervical neoplasms:2||Diseasefree survival:2||Concurrent chemoradiation:2||Laparoscopic myomectomy:2||therapeutic vaccine:2||FGF19:2||FGFR4:2||Topotecan:2||Laparotomy:2||Myoma:2||Prognoses:2||Tremelimumab:2||HPV 16:2||HPV 18:2||USP10:2||Uterine Cervical Neoplasms:2||laparotomy:2||Drug therapy:2||Neoplasm metastasis:2||Propensity ScoreMatching:2||Uterine cervical neoplasm:2||Durvalumab:2||Uterine leiomyoma:2||Neoplasm staging:2||Local:2||Choriocarcinoma:2||Histology:2||methylation:2||Radiation:2||microarray:2||Elderly:2||Endometrial Cancer:2||Lymph nodes:2||adjuvant treatment:2||Operative outcome:2||Lymphatic metastasis:2||Outcome:2||overall survival:2||Galectin1:2||Ovarian function:2||Lynch syndrome:2||Risk factors:2||Ifosfamide:2||Robotics:2||cMet:2||Ovarian transposition:2||Ovarian tumor:2||carcinoma:2||Ovary:2||Bartholin glands:2||Immunohistochemistry:2||Immunotherapy:2||Endometrial neoplasms:2||cervix neoplasms:2||Galectin7:1||Gene expression signature:1||Genetic profiling:1||Geriatric:1||Gestational trophoblastic disease:1||Glucose:1||Grade 3 endometr:1||Granulosa cell tumor:1||Gynecologic Surgical Procedures:1||Gynecologic laparoscopy:1||Gynecologic malignancy:1||Gynecologic neoplasms:1||Gynecological disease:1||Gynecological surgery:1||HER2:1||HER3:1||HIF2α:1||HIFU:1||HPV DNA tests:1||HPV genotypes:1||HPV infection:1||Hemoglobins:1||High tesla magnetic resonance imaging:1||Highgrade serous carcinoma:1||Highrisk pathologic findings:1||Homologous recombination repair:1||Human Papillomavirus:1||Human genome:1||Humanized:1||Hypercalcaemia:1||Hyperthermic Intraperitoneal Chemotherapy:1||Hypoxia:1||ID2:1||Image analysis:1||Imageguided brachytherapy:1||Immunotherapy Recurrence:1||Inclusion:1||Intermediate risk:1||International Federation of Gynecology and Obstetrics:1||Intraoperative Complications:1||Intraperitoneal Chemotherapy:1||Intraperitoneal bupivacaine:1||Invasive implant:1||Korean Gynecologic Oncology Group:1||Koreans:1||LGESS:1||La:1||Labor:1||Laminin receptor:1||Laparoendoscopic singlesite surgery (LESS):1||Laparoscopicassisted vaginal hysterectomy:1||Laparoscopicassisted vaginal hysterectomy (LAVH):1||Laparoscopically assisted vaginal hysterectomy:1||Late complications:1||Learning curve:1||Leiomyoma:1||Leiomyosarcoma:1||Length of stay:1||Less invasive surgery:1||Losartan:1||Low anterior resection:1||Low malignant:1||Low risk:1||Lymph:1||Lymph Node Metastasis:1||Lymph node:1||Lymph node dissection:1||Lymph node metastasis:1||Lymphadenectomy:1||Lymphangiogenesis:1||Lymphangitis carcinomatosa:1||Lymphocytes:1||Lymphovascular space invasion:1||MRI:1||Machine Learning:1||Manuals as Topic:1||MatchedPair Analysis:1||Melanoma:1||Menopause:1||Mesonephric adenocarcinoma:1||Metabolic syndrome:1||Metastasis:1||Metastatic carcinoma:1||MiR200 family:1||MiTMAB:1||Microarray:1||Microenvironment:1||Midline laparotomy:1||Minimal invasive surgery:1||Minimally invasive surgical procedure:1||Mirvetuximab Soravtansine:1||Modified suture technique:1||Molecular Targeted Therapy:1||Molecular ta:1||Molecular targeted therapy:1||Monoclonal:1||Monocytes:1||Mucin 1:1||Mucinous cystadenoma:1||Mucinous tumors:1||Multivariate analysis:1||Myomectomy:1||Neoadjuvant therapy:1||Neoplasm Recurrence:1||Neoplasm invasiveness:1||Neoplasm recurrence:1||Neoplasms:1||Neoplastic stem cells:1||Neutrophils:1||New classification:1||Nomograms:1||Nondiabetic:1||Nonsmall cell lung cancer:1||Nongestational:1||Normalsized Ovarian Carcinoma:1||Nuclear staining:1||OCT4:1||OcTMAB:1||OctoPort:1||Omeprazole:1||Oncology:1||Operative time:1||Optimal debulking surgery:1||Ovarian carcinoma:1||Ovarian epithelial cancer:1||Ovarian metastasis:1||Ovarian metastatectomy:1||Ovarian neoplas:1||Ovarian serous carci:1||Overall survival:1||PARP inhibitor:1||PAUF:1||PET:1||POM121:1||Pain:1||Paraaortic lymphadenectomy:1||Parametrium:1||Pathology:1||Pathology Section:1||Patientderived xenograft model:1||Pembrolizumab:1||Peritoneal tuberculosis:1||Persistent infection:1||Pharmacogenomic analysis:1||Placental site trophoblastic tumor:1||Platinum Resistant:1||Platinumfree interval:1||Platinumresistant ovarian cancer:1||Pleural effusion:1||Poly (ADPribose) Polymerase Inhibitor:1||Poly(ADPribose) Polymerase (PARP) Inhibitor:1||Poly(ADPribose) Polymerase Inhibitors:1||Postoperative computed tomography:1||Practice Guideline:1||Precision medicine:1||Prediction:1||Primary peritoneal cancer:1||Primary repair:1||Progestin:1||Prognostic factors:1||Prognostic model:1||Progression to invasive carcinoma:1||ProgressionFree Survival:1||Propensity Score:1||Proportional hazards models:1||Protein array analysis:1||Proton pump inhibitors:1||Pulmonary lymphangitic carcinomatosis:1||Pulmonary recruitment maneuver:1||Pulmonary type:1||Questionnaires:1||RARβ:1||RNA integrity:1||RNAseq:1||RPPA:1||Radiation therapy:1||Radical Trachele:1||Radical surgery:1||Radical trachelectomy:1||Radioresistance:1||Ramosetron:1||Rare cancers:1||Rectal:1||Recurrencefree survival:1||Recurrent epithelial ovarian cancer:1||Residual tumor:1||Resistance:1||Response rate:1||Retinoic acid receptors:1||Retroperitoneal space:1||Retrospective studies:1||Revised FIGO staging:1||Risk factor for recurrence:1||Riskeducing Salpingooophorectomy:1||Riskreducing salpingooophorectomy:1||Sphase:1||SCP3:1||SOX2:1||SPA:1||SUVmax:1||Salvage Therapy:1||Sarcoma, epithelioid:1||Secondary cytoreductive surgery:1||Sedlis criteria:1||Sensitivity:1||Serous cystadenoma:1||Sexuality and Gynecologic Cancer:1||Shoulder pain:1||Single port:1||Singleport access (SPA):1||Singleport access (SPA) surgery:1||Singleport myomectomy:1||Small cell carcinoma ovary:1||Small interfering RNA:1||Squamous cell lesions:1||Stage I endometrial cancer:1||Subcutaneous drain:1||Subrenal capsule implantation:1||Subtotal hysterectomy:1||Surgery, gynecological:1||Surgical Instruments:1||Surveys:1||Survival analysis:1||Survival benefit:1||Synchronous gynecologic tumor:1||TCGA:1||THZ1:1||TIP (paclitaxel, ifosfamide, cisplatin):1||TP53 mutations:1||Therapeutic target:1||Thiazides:1||Tolllike receptor 5:1||Toxicity:1||Trastuzumab Deruxtecan:1||Treatment:1||Treatment interval:1||Treatment outcome:1||Tumor biomarkers:1||Tumor invasion:1||Tumor marker:1||Uterine artery ligation:1||Uterine carcinoma:1||Uterine carcinosarcomas:1||Uterine cervix:1||Uterine neoplasm:1||Uterine papillary serous carcinomas:1||Uterine rupture:1||VATPase:1||VAS score:1||Vacuolar protontranslocating ATPases:1||Vaginal birth after cesarean section (VBAC):1||Variant of unknown significance:1||Vascular endothelial growth factor:1||Villoglandular adenocarcinoma:1||Vulva neoplasms:1||Vulvar cancer:1||WNT:1||Waiting time:1||Wound dehiscence:1||Wound infection:1||aCGH:1||adenoid cystic carcinoma:1||adjuvant chemotherapy:1||adnexectomy:1||advanced ovarian cancer:1||adverse effects:1||alcohol:1||ancestry:1||anemia:1||animal model:1||anticancer agent:1||articulating:1||ascites:1||baseline lymphocyte count:1||belotecan:1||biomarker:1||biomarkers:1||borderline ovarian tumor:1||borderline ovarian tumour:1||brain metastases:1||breast neoplasms:1||bulky cervical cancer:1||bulky cervical carcinoma:1||cancer metastasis:1||carboplatin:1||cervical carcinoma:1||cervical cytology:1||cervical neoplasia:1||cervical ripening:1||cervical squamous cell carcinoma:1||chemoradioresistance:1||clear cell adenocarcinoma:1||clear cell carcinoma:1||clinical trial:1||clinical trials, phase II as topic:1||co:1||colorectal cancer:1||combination:1||complete blood count:1||complication:1||computed tomographic scan:1||concurrent chemoradiotherapy:1||conization:1||consolidation chemotherapy:1||cystectomy:1||cytoreductive surgery:1||diseasefree survival:1||dynamin 2:1||endocytosis:1||erythropoietin:1||expression microarray:1||fertilitysparing surgery:1||fixation:1||followup studies:1||formalin:1||galectin3:1||gammaknife radiosurgery:1||gene expression profiling:1||gene signature:1||genes:1||germline mutation:1||gynecologic cancer:1||gynecology:1||highdoserate brachytherapy:1||histologic subtype:1||histology:1||histomorphology:1||homologous recombination repair mutation:1||human epidermal growth factor receptor:1||immune checkpoint inhibitor:1||immune checkpoint inhibitors:1||immunotherapy:1||inclusion:1||indirect immunization:1||laparoendoscopic singlesite:1||laparoscopic single site surgery:1||laparoscopically assisted vaginal hysterectomy:1||large ovarian tumor:1||leiomyosarcoma:1||locally advanced cervical cancer:1||locally advanced cervical carcinoma:1||loss of heterozygosity:1||lymph node:1||lymph nodes:1||lymphadenectomy:1||lysyltRNA synthetase:1||mTOR:1||machine learning:1||magnetic resonance imaging:1||maintenance therapy:1||matrix metalloproteinase2:1||mature cystic teratoma:1||metastasis:1||metastatic carcinoma:1||miR155:1||minimally invasive surgery:1||minimallyinvasive surgery:1||misoprostol:1||mitomycinC:1||monocyte:1||myoma:1||neoadjuvant chemotherapy:1||neoplasm invasiveness:1||neoplasms:1||olaparib:1||olaparibbased combination:1||oral:1||oregovomab:1||outcome:1||ovarian neoplasm:1||ovarian ser:1||ovary of normal size:1||pSTAT3:1||p14ARF:1||p53:1||papillary serous carcinoma:1||paraaortic lymph node:1||paraffin embedded:1||patient care bundles:1||perioperative care:1||platinumresistant:1||platinumresistant recurrent ovarian cancer:1||pmTOR:1||polyADP ribose polymerase inhibitor:1||postoperative complications:1||prediction of optimal cytoreduction:1||pregnancy:1||primary cytoreductive surgery:1||primary peritoneal carcinoma:1||programmed cell death 1 receptor:1||progression:1||promoter hypermethylation:1||propensity score matching:1||protein expression:1||proteinprotein interaction:1||quantitative trait loci:1||reactive thrombocytosis:1||realtime RTPCR:1||recurrent cervical carcinoma:1||recurrent epithelial ovarian cancer:1||recurrent ovarian epithelial carcinoma:1||regression:1||residual:1||resistant:1||retroperitoneal space:1||single port access:1||singlenucleotide polymorphism:1||singleport access:1||small intestinal adenocarcinoma:1||splenectomy:1||squamous epithelium:1||stage IB1:1||statistical model:1||sublingual:1||survival rate:1||therapeutic target:1||tissue:1||tolllike receptor:1||toxicity:1||treatment:1||treatment efficacy:1||treatment outcome:1||tumor suppressor genes:1||umbrella study:1||unilateral salpingooophorectomy:1||uterine cervical neoplasm:1||uterine neoplasms:1||uterus:1||vaginal:1||vincristine:1||.:1||vulvar cancer:1||AGR2:1||AGTR1:1||AMPactivated protein kinase:1||ANXA2:1||ANXA4:1||Accuracy:1||Adenocarcinoma in situ:1||Adenoid cystic carcinoma:1||Adjuvant:1||Adjuvant chemotherapy:1||Adjuvant treatment:1||Adnexal surgery:1||Adrenergic betaantagonists:1||Advanced ovarian cancer:1||Advancedstage:1||Adverse effects:1||Aged:1||Anemia:1||Aneuploidy:1||Angiotensin II type 1 receptor blockers:1||Annexin A4:1||Antibodies:1||Antibody antiCA125:1||Antihypertensive agents:1||Antineoplastic agents:1||Appendectomy:1||Appendix:1||Aprepitant:1||Ascites:1||Atypical endometrial hyperplasia:1||B cell:1||BRCA mutation:1||BRCA1 gene:1||BRCA1 genes:1||BRCA2 gene:1||BRCA2 genes:1||BRD7:1||BSO:1||BVACC:1||Benign metastasizing leiomyoma:1||Benign ovarian tu:1||Beta blocker:1||Biological markers:1||Biomarker:1||Bladder dissection technique:1||Bone metastasis:1||Borderline tumor:1||Breast cancer:1||Bulky Lymph Node:1||CA125 Antigen:1||CA125:1||CA199:1||CAIX:1||CTR1:1||CTR2:1||Calcium channel blockers:1||Cancer:1||Carbohydrate Antigen 125:1||Carcinogenesis:1||Carcinoma in situ:1||Casecontrol study:1||Cervical Cytology:1||Cervical neoplasm:1||Cervix:1||Cervix uteri:1||Cesarean section:1||Chemoradiotherapy:1||Chemoresistance:1||ClavienDind:1||Clear Cell Carcinoma:1||Clinical study:1||Cluster analysis:1||Colon:1||Colposcopy:1||Complete response:1||Complication:1||Concurrent Chemoradiotherapy:1||Conservative surgery:1||Conventional:1||Cyclindependent kinase 7:1||Cystectomy:1||Cytodiagnosis:1||Cytoreduction surgical procedures:1||Cytoreductive Surgery:1||DASL assay:1||DD6:1||Dexamethasone:1||Diagnosis:1||Diagnostic Techniques and Procedures:1||Diagnostic imaging:1||Diffusionweighted imaging:1||Discrepancy:1||Disease free survival:1||Double primary cancers:1||Drug resistance:1||Dynamin 2:1||Dynasore:1||E:1||ENOTES:1||ERCC1:1||Endocervix:1||Endometrial Hyperplasia:1||Endometrial Neoplasms:1||Endometrial ca:1||Endometrial intraepithelial neoplasia:1||Endometrial stromal sarcoma:1||Endometrioid Carcinoma:1||Endometrioid carcinoma:1||Endometriosis:1||Endoscopic stapler:1||Enhanced recovery after surgery (ERAS):1||Epithelial endometrial carcinomas:1||Epithelial membrane antigen:1||Epithelial ovarian tumors:1||Esomeprazole:1||Etoposide:1||FIGO:1||FIGO stage:1||FIGO staging:1||FSH:1||FTY720:1||Fertility:1||Fertility sparing:1||Fertilitysparing surgery:1||Fertilitysparing treatment:1||Fibroblast growth factor receptor:1||Flow cytometry:1||Fluorodeoxyglucose F18:1||Frozen section:1||GOG criteria:1||

STATISTICS: Total View:; Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE